DUBLIN, Feb 14, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Tuberculosis Diagnostics and Treatment Market Analysis & Trends- Therapeutics, Diagnosis - Forecast to 2025" report to their offering.

The Global Tuberculosis Diagnostics and Treatments Market is poised to grow at a CAGR of around 4.2% from 2015 to 2025

Some of the prominent trends that the market is Technologies that may replace smear microscopy continue to expand, Major investments in basic research related to Mycobaterium tuberculosis diagnosis, Demand for Xpert MTB/RI in the tuberculosis diagnostics landscape and Potential Market in Most of the Emerging Nations of the World.

Based on Therapeutics the market is categorized into Tuberculosis Drugs (First Line) and Tuberculosis Drugs (Second Line). The Tuberculosis Drugs (First Line) segment is Isoniazid (INH), Rifampin (RIF), Ethambutol (EMB) and Pyrazinamide (PZA). Tuberculosis Drugs (Second Line) segment is further represented as Aminoglycosides, Fluoroquinolones, Polypeptides, Thioamides, Cycloserine, p-Aminosalicylic Acid and Other Drugs.

Based on Diagnosis the market is categorized into Skin Testing and Laboratory Testing. The Laboratory Testing segment is further categorized into Adenosine Deaminas, Nucleic Acid Amplification Tests (NAAT), Interferon Gamma Release Assay, Antibody/Antigen Detection, Culture-Based Systems, Non-Culture Methods, Chest X-rays and computer-aided diagnosis, Biomarkers for active or latent TB, Serodiagnostic assays, Microscopy and associated tools, Cytokine detection assay, Smear Microscopy and Drug Susceptibility Testing (DST).

This industry report analyzes the global markets for Tuberculosis Diagnostics across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

Key Topics Covered:

1 Market Outline

1.1 Research Methodology

1.1.1 Research Approach & Sources

1.2 Market Trends

1.3 Regulatory Factors

1.4 End User Analysis

1.5 Application Analysis

1.6 Strategic Benchmarking

1.7 Opportunity Analysis

2 Executive Summary

3 Market Overview

3.1 Current Trends

3.1.1 Technologies that may replace smear microscopy continues to expand

3.1.2 Major investments in basic research related to Mycobacterium tuberculosis diagnosis

3.1.3 Demand for Xpert MTB/RI in the tuberculosis diagnostics landscape

3.1.4 Potential Market in Most of the Emerging Nations of the World

3.2 Drivers

3.3 Constraints

3.4 Industry Attractiveness

4 Tuberculosis Diagnostics and Treatments Market, By Therapeutics

4.1 Tuberculosis Drugs (First Line)

4.1.1.1 Isoniazid (INH)

4.1.1.2 Rifampin (RIF)

4.1.1.3 Ethambutol (EMB) 

4.1.1.4 Pyrazinamide (PZA)

4.2 Tuberculosis Drugs (Second Line)

4.2.1.1 Aminoglycosides 

4.2.1.2 Fluoroquinolones 

4.2.1.3 Polypeptides 

4.2.1.4 Thioamides 

4.2.1.5 Cycloserine 

4.2.1.6 p-Aminosalicylic Acid

4.2.1.7 Other Drugs

5 Tuberculosis Diagnostics and Treatments Market, By Diagnosis

5.1 Skin Testing 

5.2 Laboratory Testing 

5.2.1.1 Adenosine Deaminase

5.2.1.2 Nucleic Acid Amplification Tests (NAAT)

5.2.1.3 Interferon Gamma Release Assay

5.2.1.4 Antibody/Antigen Detection

5.2.1.5 Culture-Based Systems

5.2.1.6 Non-Culture Methods

5.2.1.7 Chest X-rays and computer-aided diagnosis

5.2.1.8 Biomarkers for active or latent TB

5.2.1.19 Serodiagnostic assays

5.2.1.10 Microscopy and associated tools

5.2.1.11 Cytokine detection assay

5.2.1.12 Smear Microscopy

5.2.1.13 Drug Susceptibility Testing (DST)

6 Tuberculosis Diagnostics and Treatments Market, By Geography 

7 Key Player Activities

7.1 Acquisitions & Mergers

7.2 Agreements, Partnerships, Collaborations and Joint Ventures

7.3 Product Launch & Expansions

7.4 Other Activities

8 Leading Companies

8.1 Cepheid Inc

8.2 Becton Dickinson

8.3 Hain LifeSciences

8.4 Abbott Laboratories,

8.5 Alere, Inc

8.6 F. Hoffmann-La Roche AG

8.7 Hologic Corporation

8.8 bioMérieux SA

8.9 Sanofi

8.10 QIAGEN

8.11 Akonni Biosystems, Inc.

8.12 Epistem Holdings Plc

8.13 Gen-Probe Inc.

8.14 EIKEN Chemical

8.15 Thermo Fisher Scientific, Inc

For more information about this report visit http://www.researchandmarkets.com/research/s4rkm8/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets